276 related articles for article (PubMed ID: 24796767)
1. Is it possible to change phenotype progression in Crohn's disease in the era of immunomodulators? Predictive factors of phenotype progression.
Magro F; Rodrigues-Pinto E; Coelho R; Andrade P; Santos-Antunes J; Lopes S; Camila-Dias C; Macedo G
Am J Gastroenterol; 2014 Jul; 109(7):1026-36. PubMed ID: 24796767
[TBL] [Abstract][Full Text] [Related]
2. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project.
Cleynen I; González JR; Figueroa C; Franke A; McGovern D; Bortlík M; Crusius BJ; Vecchi M; Artieda M; Szczypiorska M; Bethge J; Arteta D; Ayala E; Danese S; van Hogezand RA; Panés J; Peña SA; Lukas M; Jewell DP; Schreiber S; Vermeire S; Sans M
Gut; 2013 Nov; 62(11):1556-65. PubMed ID: 23263249
[TBL] [Abstract][Full Text] [Related]
3. Early surgery in Crohn's disease patients with entero-urinary fistulas: does it change the prognosis?
Coelho R; Magro F; Silva M; Macedo G
Scand J Gastroenterol; 2016; 51(6):679-83. PubMed ID: 26679346
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic features of Crohn's disease associated with failure of medical treatment.
Moran GW; Dubeau MF; Kaplan GG; Yang H; Seow CH; Fedorak RN; Dieleman LA; Barkema HW; Ghosh S; Panaccione R;
Clin Gastroenterol Hepatol; 2014 Mar; 12(3):434-42.e1. PubMed ID: 23978351
[TBL] [Abstract][Full Text] [Related]
5. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009.
Lakatos PL; Golovics PA; David G; Pandur T; Erdelyi Z; Horvath A; Mester G; Balogh M; Szipocs I; Molnar C; Komaromi E; Veres G; Lovasz BD; Szathmari M; Kiss LS; Lakatos L
Am J Gastroenterol; 2012 Apr; 107(4):579-88. PubMed ID: 22233693
[TBL] [Abstract][Full Text] [Related]
6. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease.
Lakatos PL; Czegledi Z; Szamosi T; Banai J; David G; Zsigmond F; Pandur T; Erdelyi Z; Gemela O; Papp J; Lakatos L
World J Gastroenterol; 2009 Jul; 15(28):3504-10. PubMed ID: 19630105
[TBL] [Abstract][Full Text] [Related]
7. A risk score system to timely manage treatment in Crohn's disease: a cohort study.
Pallotta N; Vincoli G; Pezzotti P; Giovannone M; Gigliozzi A; Badiali D; Vernia P; Corazziari ES
BMC Gastroenterol; 2018 Nov; 18(1):164. PubMed ID: 30400823
[TBL] [Abstract][Full Text] [Related]
8. Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index.
Bodini G; Giannini EG; De Maria C; Dulbecco P; Furnari M; Marabotto E; Savarino V; Savarino E
Dig Liver Dis; 2017 Feb; 49(2):175-180. PubMed ID: 27864028
[TBL] [Abstract][Full Text] [Related]
9. Crohn's disease and smoking: is it ever too late to quit?
Lawrance IC; Murray K; Batman B; Gearry RB; Grafton R; Krishnaprasad K; Andrews JM; Prosser R; Bampton PA; Cooke SE; Mahy G; Radford-Smith G; Croft A; Hanigan K
J Crohns Colitis; 2013 Dec; 7(12):e665-71. PubMed ID: 23790611
[TBL] [Abstract][Full Text] [Related]
10. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial.
Cosnes J; Bourrier A; Laharie D; Nahon S; Bouhnik Y; Carbonnel F; Allez M; Dupas JL; Reimund JM; Savoye G; Jouet P; Moreau J; Mary JY; Colombel JF;
Gastroenterology; 2013 Oct; 145(4):758-65.e2; quiz e14-5. PubMed ID: 23644079
[TBL] [Abstract][Full Text] [Related]
11. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis.
Szamosi T; Banai J; Lakatos L; Czegledi Z; David G; Zsigmond F; Pandur T; Erdelyi Z; Gemela O; Papp M; Papp J; Lakatos PL
Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):872-9. PubMed ID: 19648821
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of patients with Crohn's disease who respond to azathioprine.
Camus M; Seksik P; Bourrier A; Nion-Larmurier I; Sokol H; Baumer P; Beaugerie L; Cosnes J
Clin Gastroenterol Hepatol; 2013 Apr; 11(4):389-94. PubMed ID: 23142207
[TBL] [Abstract][Full Text] [Related]
13. Lower Risk of B1-to-pB3-Stage Migration in Crohn's Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study.
Cernoch PS; Fournier N; Zeitz J; Scharl M; Morell B; Greuter T; Schreiner P; Misselwitz B; Safroneeva E; Schoepfer AM; Vavricka SR; Rogler G; Biedermann L;
Dig Dis Sci; 2020 Sep; 65(9):2654-2663. PubMed ID: 31797187
[TBL] [Abstract][Full Text] [Related]
14. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study.
Chebli JM; Gaburri PD; De Souza AF; Pinto AL; Chebli LA; Felga GE; Forn CG; Pimentel CF
J Gastroenterol Hepatol; 2007 Feb; 22(2):268-74. PubMed ID: 17295882
[TBL] [Abstract][Full Text] [Related]
15. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
Baert F; Moortgat L; Van Assche G; Caenepeel P; Vergauwe P; De Vos M; Stokkers P; Hommes D; Rutgeerts P; Vermeire S; D'Haens G; ;
Gastroenterology; 2010 Feb; 138(2):463-8; quiz e10-1. PubMed ID: 19818785
[TBL] [Abstract][Full Text] [Related]
16. Levels of anti-double-strained DNA but not antinuclear antibodies are associated with treatment efficacy and adverse outcomes in Crohn's disease patients treated with anti-TNFα.
Kiss LS; Lovasz BD; Golovics PA; Vegh Z; Farkas K; Molnar T; Palatka K; Papp M; Mohas A; Szilagyi BK; Fekete SA; Mandel M; Lakatos PL
J Gastrointestin Liver Dis; 2013 Jun; 22(2):135-40. PubMed ID: 23799211
[TBL] [Abstract][Full Text] [Related]
17. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
18. Evolution of disease phenotype in adult and pediatric onset Crohn's disease in a population-based cohort.
Lovasz BD; Lakatos L; Horvath A; Szita I; Pandur T; Mandel M; Vegh Z; Golovics PA; Mester G; Balogh M; Molnar C; Komaromi E; Kiss LS; Lakatos PL
World J Gastroenterol; 2013; 19(14):2217-26. PubMed ID: 23599648
[TBL] [Abstract][Full Text] [Related]
19. Immediate prophylactic vs endoscopic or symptomatic-driven azathioprine treatment to prevent surgical recurrence after intestinal resection for Crohn's disease.
Guo Z; Cai X; Liu R; Gong J; Li Y; Cao L; Wang Z; Zhu W
Colorectal Dis; 2018 Sep; 20(9):O267-O276. PubMed ID: 30051962
[TBL] [Abstract][Full Text] [Related]
20. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease.
Marehbian J; Arrighi HM; Hass S; Tian H; Sandborn WJ
Am J Gastroenterol; 2009 Oct; 104(10):2524-33. PubMed ID: 19532125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
